ID29285A - PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS - Google Patents

PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS

Info

Publication number
ID29285A
ID29285A IDW20002551A ID20002551A ID29285A ID 29285 A ID29285 A ID 29285A ID W20002551 A IDW20002551 A ID W20002551A ID 20002551 A ID20002551 A ID 20002551A ID 29285 A ID29285 A ID 29285A
Authority
ID
Indonesia
Prior art keywords
ribavirin
ifn
peg
treatment
chronic hepatitis
Prior art date
Application number
IDW20002551A
Other languages
English (en)
Indonesian (id)
Inventor
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ID29285A publication Critical patent/ID29285A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IDW20002551A 1998-06-08 1999-05-29 PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS ID29285A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08

Publications (1)

Publication Number Publication Date
ID29285A true ID29285A (id) 2001-08-16

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002551A ID29285A (id) 1998-06-08 1999-05-29 PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS

Country Status (35)

Country Link
US (3) US20030053986A1 (es)
EP (1) EP1087778B1 (es)
JP (2) JP3839667B2 (es)
KR (2) KR20050055053A (es)
CN (1) CN1170543C (es)
AR (1) AR019855A1 (es)
AT (1) ATE307597T1 (es)
AU (1) AU767131B2 (es)
BR (1) BR9911076A (es)
CA (1) CA2334267C (es)
CL (1) CL2010000828A1 (es)
CO (1) CO5050297A1 (es)
CZ (1) CZ298681B6 (es)
DE (1) DE69927971T2 (es)
DK (1) DK1087778T3 (es)
ES (1) ES2251196T3 (es)
HK (1) HK1037981A1 (es)
HR (1) HRP20000808A2 (es)
HU (1) HU228218B1 (es)
ID (1) ID29285A (es)
IL (2) IL139786A0 (es)
MA (1) MA26641A1 (es)
MY (1) MY124091A (es)
NO (1) NO325598B1 (es)
NZ (1) NZ508249A (es)
PE (1) PE20000560A1 (es)
PL (1) PL192364B1 (es)
RS (1) RS50144B (es)
RU (1) RU2271217C2 (es)
SA (1) SA99200208B1 (es)
SI (1) SI1087778T1 (es)
TR (1) TR200003635T2 (es)
TW (1) TWI241913B (es)
WO (1) WO1999064016A1 (es)
ZA (1) ZA200006814B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251196T3 (es) * 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
IL154299A0 (en) * 2000-08-07 2003-09-17 Sciclone Pharmaceuticals Inc Treatment of hepatitis c with thymosin, interferon and ribavirin
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
MXPA04012709A (es) 2002-06-28 2005-09-30 Idenix Cayman Ltd Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2005533824A (ja) * 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
WO2004052899A2 (en) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
AU2003300434A1 (en) * 2002-12-23 2004-07-22 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
WO2005003147A2 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US8615282B2 (en) 2004-07-13 2013-12-24 Dexcom, Inc. Analyte sensor
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1917037A2 (en) * 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn alpha and ribavirin for hbv treatment
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
AU2009264214B2 (en) 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
WO2010033443A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
RU2012107812A (ru) 2009-08-05 2013-09-10 Аллерган, Инк. Препараты мутеинов липокалинов с контролируемым высвобождением
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
SG10201408073XA (en) 2009-12-07 2015-01-29 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
EP2606061B8 (en) 2010-08-16 2017-09-27 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
WO2012072806A1 (en) 2010-12-02 2012-06-07 Pieris Ag Muteins of human lipocalin 2 with affinity for ctla-4
ME03009B (me) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Metode za lecenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2858962C (en) 2011-12-13 2023-09-05 Pieris Ag Compositions of human tear lipocalin muteins and methods of use thereof
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
JP2015508418A (ja) 2013-01-31 2015-03-19 ギリアド ファーマセット エルエルシー ２種の抗ウイルス化合物のコンビナトリアル製剤
US9150629B2 (en) 2013-03-14 2015-10-06 Daiichi Sankyo Co., Ltd. Human tear lipocalins which bind PCSK9 and methods of use thereof
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CN106573964B (zh) 2014-05-22 2021-07-16 皮里斯制药有限公司 新型特异性结合多肽及其用途
BR112017015773A2 (pt) 2015-01-28 2018-03-27 Pieris Pharmaceuticals Gmbh muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
MA41072A1 (fr) 2015-02-18 2018-10-31 Sanofi Sa Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
SG11201708334RA (en) 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CN114573680A (zh) 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
MX2017014716A (es) 2015-05-18 2018-06-28 Pieris Pharmaceuticals Gmbh Polipeptido de fusion anti-cancer.
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
MX2018000447A (es) 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
JP2019505565A (ja) 2015-11-30 2019-02-28 ピエリス オーストラリア プロプライエタリー リミテッド 新規の抗血管新生融合ポリペプチド
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US11168119B2 (en) 2017-01-18 2021-11-09 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for LAG-3
TWI837156B (zh) 2018-07-31 2024-04-01 德商皮里斯製藥有限公司 新穎的cd137及pd-l1特異性融合蛋白
MX2021010039A (es) 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
WO2021245240A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
BR112023020859A2 (pt) 2021-04-08 2023-12-12 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina específicas para fator de crescimento do tecido conjuntivo (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0730470B1 (en) * 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
ES2251196T3 (es) * 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.

Also Published As

Publication number Publication date
NO20006178D0 (no) 2000-12-05
CA2334267C (en) 2009-02-17
IL139786A0 (en) 2002-02-10
KR20010052622A (ko) 2001-06-25
SA99200208B1 (ar) 2006-08-15
DE69927971D1 (de) 2005-12-01
EP1087778B1 (en) 2005-10-26
JP2002517451A (ja) 2002-06-18
HRP20000808A2 (en) 2001-10-31
NO20006178L (no) 2000-12-05
US20030053986A1 (en) 2003-03-20
MY124091A (en) 2006-06-30
ZA200006814B (en) 2002-05-03
PL344794A1 (en) 2001-11-19
CO5050297A1 (es) 2001-06-27
IL139786A (en) 2007-10-31
AR019855A1 (es) 2002-03-20
US20070196385A1 (en) 2007-08-23
TR200003635T2 (tr) 2001-04-20
KR20050055053A (ko) 2005-06-10
RS50144B (sr) 2009-03-25
YU77000A (sh) 2003-08-29
HUP0102033A2 (hu) 2001-10-28
RU2271217C2 (ru) 2006-03-10
SI1087778T1 (sl) 2006-02-28
CZ20004487A3 (en) 2001-06-13
TWI241913B (en) 2005-10-21
PE20000560A1 (es) 2000-07-05
JP3839667B2 (ja) 2006-11-01
ES2251196T3 (es) 2006-04-16
HU228218B1 (en) 2013-02-28
DK1087778T3 (da) 2005-12-19
WO1999064016A1 (en) 1999-12-16
US20050031589A1 (en) 2005-02-10
MA26641A1 (fr) 2004-12-20
CZ298681B6 (cs) 2007-12-19
CL2010000828A1 (es) 2011-02-11
EP1087778A1 (en) 2001-04-04
BR9911076A (pt) 2001-02-20
HUP0102033A3 (en) 2010-01-28
NZ508249A (en) 2003-02-28
PL192364B1 (pl) 2006-10-31
HK1037981A1 (en) 2002-03-01
CA2334267A1 (en) 1999-12-16
CN1305382A (zh) 2001-07-25
DE69927971T2 (de) 2006-07-27
ATE307597T1 (de) 2005-11-15
AU4503399A (en) 1999-12-30
NO325598B1 (no) 2008-06-23
AU767131B2 (en) 2003-10-30
CN1170543C (zh) 2004-10-13
JP2006160759A (ja) 2006-06-22

Similar Documents

Publication Publication Date Title
ID29285A (id) PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
DE69801970D1 (de) Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
MA26668A1 (fr) ACTIVATEURS DE hPPARy ET hPPARa
ID26935A (id) Penyemprot cairan dan nozel sisipan
ID23646A (id) Benda penyerap cairan tubuh sekali pakai
ID24147A (id) Benda penyerap cairan tubuh sekali pakai
EE9900003A (et) Meetod ja seade anduri fikseerimiseks kehasiseses luumenis
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
DE69927464D1 (de) Körperflüssigkeiten absorbierender Wegwerfartikel
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
ID24196A (id) Komposisi dan penggunaan
PT1164996E (pt) Sistemas terapeuticos transdermicos com nicotina e adicao de cetonas monoterpenicas
ID26297A (id) Celana jenis celana pendek sekali pakai dan proses pembuatannya
ID23258A (id) Penarik pemberian-menyilang dan metodenya
ID24463A (id) Metode meningkatkan ketersediaan hayati feksofenadin dan turunan-turunannya
DE69918447D1 (de) Antivirale kombinationen von lamivudin und adefovir
ID28797A (id) Tioredoksin dan pemrosesan biji-bijian
NO20006444L (no) Referanseforbindelse for anvendelse i ananlyser av levosimendanporsjoner
UA25852C2 (uk) Пристрій для діяhhя hа потік плиhhого середовища
ID18913A (id) Turunan turunan tienopiridin dan penggunaannya
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
ID29414A (id) Pengobatan depresi
NO20000274D0 (no) Behandling av fluider
ID28262A (id) Komposisi herbal untuk propilaksis dan pengobatan aids